X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
17
PharmaCompass offers a list of Deferoxamine Mesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Deferoxamine Mesylate manufacturer or Deferoxamine Mesylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Deferoxamine Mesylate manufacturer or Deferoxamine Mesylate supplier.
PharmaCompass also assists you with knowing the Deferoxamine Mesylate API Price utilized in the formulation of products. Deferoxamine Mesylate API Price is not always fixed or binding as the Deferoxamine Mesylate Price is obtained through a variety of data sources. The Deferoxamine Mesylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Deferoxamine Mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Deferoxamine Mesylate, including repackagers and relabelers. The FDA regulates Deferoxamine Mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Deferoxamine Mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Deferoxamine Mesylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Deferoxamine Mesylate supplier is an individual or a company that provides Deferoxamine Mesylate active pharmaceutical ingredient (API) or Deferoxamine Mesylate finished formulations upon request. The Deferoxamine Mesylate suppliers may include Deferoxamine Mesylate API manufacturers, exporters, distributors and traders.
click here to find a list of Deferoxamine Mesylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Deferoxamine Mesylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Deferoxamine Mesylate active pharmaceutical ingredient (API) in detail. Different forms of Deferoxamine Mesylate DMFs exist exist since differing nations have different regulations, such as Deferoxamine Mesylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Deferoxamine Mesylate DMF submitted to regulatory agencies in the US is known as a USDMF. Deferoxamine Mesylate USDMF includes data on Deferoxamine Mesylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Deferoxamine Mesylate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Deferoxamine Mesylate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Deferoxamine Mesylate Drug Master File in Japan (Deferoxamine Mesylate JDMF) empowers Deferoxamine Mesylate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Deferoxamine Mesylate JDMF during the approval evaluation for pharmaceutical products. At the time of Deferoxamine Mesylate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Deferoxamine Mesylate suppliers with JDMF on PharmaCompass.
A Deferoxamine Mesylate CEP of the European Pharmacopoeia monograph is often referred to as a Deferoxamine Mesylate Certificate of Suitability (COS). The purpose of a Deferoxamine Mesylate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Deferoxamine Mesylate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Deferoxamine Mesylate to their clients by showing that a Deferoxamine Mesylate CEP has been issued for it. The manufacturer submits a Deferoxamine Mesylate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Deferoxamine Mesylate CEP holder for the record. Additionally, the data presented in the Deferoxamine Mesylate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Deferoxamine Mesylate DMF.
A Deferoxamine Mesylate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Deferoxamine Mesylate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Deferoxamine Mesylate suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Deferoxamine Mesylate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Deferoxamine Mesylate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Deferoxamine Mesylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Deferoxamine Mesylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Deferoxamine Mesylate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Deferoxamine Mesylate suppliers with NDC on PharmaCompass.
Deferoxamine Mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Deferoxamine Mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Deferoxamine Mesylate GMP manufacturer or Deferoxamine Mesylate GMP API supplier for your needs.
A Deferoxamine Mesylate CoA (Certificate of Analysis) is a formal document that attests to Deferoxamine Mesylate's compliance with Deferoxamine Mesylate specifications and serves as a tool for batch-level quality control.
Deferoxamine Mesylate CoA mostly includes findings from lab analyses of a specific batch. For each Deferoxamine Mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Deferoxamine Mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Deferoxamine Mesylate EP), Deferoxamine Mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Deferoxamine Mesylate USP).
Market Place
